(77 days)
No
The device description and performance studies focus on mechanical application methods (dripping and spraying) and optimizing physical parameters like gas pressure and distance. There is no mention of AI or ML in the text.
No
The document describes a device used to apply a therapeutic substance (fibrin sealant), but the device itself is not a therapeutic device; it is an application device.
No
The device is an application device for a fibrin sealant, used to deliver a therapeutic substance to a surgical site on the liver. It does not perform any diagnostic function.
No
The device description clearly outlines physical components such as syringes, catheters, dispensing pins, and an air tube with a sterile filter, indicating it is a hardware device with mechanical functions.
Based on the provided information, the Crosseal™ Application Device is not an IVD (In Vitro Diagnostic) device.
Here's why:
- Intended Use: The intended use is for the topical application of a fibrin sealant onto the surface of the liver during surgery. This is a therapeutic/surgical application, not a diagnostic test performed on a sample taken from the body.
- Device Description: The device is described as a tool for applying a substance to a surgical site. It doesn't involve analyzing biological samples (like blood, urine, tissue biopsies, etc.) to diagnose a condition or provide information about a patient's health status.
- Lack of IVD Characteristics: There is no mention of the device being used to test or analyze biological specimens, nor does it produce results that would be used for diagnosis, monitoring, or screening.
Therefore, the Crosseal™ Application Device falls under the category of a surgical/therapeutic device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Crosseal™ Application Device is intended for the simultaneous topical application of the two biological components of Crosseal™ Fibrin Sealant via dripping (no air pressure) or via spraying (utilizing the pressure regulator unit) onto the surface of the liver in patients undergoing liver surgery.
Product codes
FMI
Device Description
The Crosseal" Application Device is a sterile, single-use, disposable two-syringe device used for the application by dripping or spraying of the two biological components of Crosseal "Fibrin Sealant onto the surface of the liver in patients undergoing liver surgery. . The two syringes are connected to either a dual (nonspraying) or tri-lumen (spraying) catheter. The device also has two Mixject Dispensing Pins with Detachable Vial Holders, a device that has already been cleared by the FDA through Premarket Notification [510(k)]. The Mixject is used to attach the glass vials containing the biological components for transfer into the syringes without the use of needles. For spraying, the Application Device must be connected through an air tube with a sterile filter to a supply of pressurized gas (compressed air, nitrogen, CO2) via a pressure regulator, which is an accessory to the Application Device. For dripping, the Application Device can be used with or without pressurized gas. The device is ethylene oxide (EtO) sterilized.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
surface of the liver
Indicated Patient Age Range
Not Found
Intended User / Care Setting
hospital use
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Use of the spray application technology is supported by performance testing studies that determined the optimal gas pressure range and the optimal distance that the spray catheter is required to be from the surgical tissue surface to obtain uniformity of mixing and consistency of spray spread. The optimal gas pressure (34psi) and optimal spray distance 10-15 cm was evaluated in two U.S. pivotal Phase III clinical trials. There were no adverse events associated with this system and the clinical studies demonstrated that this is an efficacious method of providing optimal coverage of fibrin sealant onto the surgical tissue surface.
Biocompatibility Tests:
- A Primary Skin Irritation Evaluation was conducted using a test extract of the device. Under the conditions of the test, the test article extract was found to not produce skin irritation.
- A Guinea Pig Maximization was performed using a test extract of the device. Under conditions of the test, the Test Article, extracted in normal saline, was found to not produce sensitization.
- A Cytotoxicity Test (MEM Elution Test) was performed using a test extract of the device. Under conditions of the test, the Test Article was found to be non-cytotoxic.
- An Acute Systemic Toxicity Test was conducted using a test extract of the device. Under conditions of the test, there was no reaction of the mice to the Test article when observed at intervals of a period of 72 hours following treatment.
- A Pyrogenicity Test (Limulus Test)-Materials Mediated, was performed using a test extract of the device. Under conditions of the test, the Test Article was found to be non-pyrogenic.
- Two studies were conducted to determine hemocompatibility: an in vitro hemolysis study (modified ASTM - Direct Contact Method) and a determination of clotting time using the Lee-White Method. The studies revealed that the test article was non-hemolytic, and did not biologically effect the clotting time.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5570 Hypodermic single lumen needle.
(a)
Identification. A hypodermic single lumen needle is a device intended to inject fluids into, or withdraw fluids from, parts of the body below the surface of the skin. The device consists of a metal tube that is sharpened at one end and at the other end joined to a female connector (hub) designed to mate with a male connector (nozzle) of a piston syringe or an intravascular administration set.(b)
Classification. Class II (performance standards).
0
510(k) SUMMARY
Submitter:
OMRIX biopharmaceuticals, Ltd. MDA blood bank, Sheba Hospital, Ramat-Gan POB 888, Kiryat Ono 55000 ISRAEL Tel: +972 3 531 6531 Fax: +972 3 535 0265
Date Summary was Prepared:
Contact Person:
Sue Bhadare CROfessionals LLC 6599 Commerce Court Suite 200, Warrenton VA 20187, USA Tel: (540) 428 2828 Fax: (540) 428 2834
March 2003
Name of Device:
Crosseal™ Application Device
Identification of Predicate Devices:
Duploject™ Baxter Healthcare Corporation, Hyland Immuno K973510
Mixject® Dispensing Pin with Detachable Vial Holder Medimop Medical Projects, Ltd. (Israel) K963283
Tissomat® and Spray Set Baxter Healthcare Corporation, Hyland Immuno K981089
Description of Device:
The Crosseal" Application Device is a sterile, single-use, disposable two-syringe device used for the application by dripping or spraying of the two biological components of Crosseal "Fibrin Sealant onto the surface of the liver in patients undergoing liver surgery. . The two syringes are connected to either a dual (nonspraying) or tri-lumen (spraying) catheter. The device also has two Mixject Dispensing Pins with Detachable Vial Holders, a device that has already been cleared by the FDA through Premarket Notification [510(k)]. The Mixject is used to attach the glass vials containing the biological components for transfer into the syringes without the use of needles. For spraying, the Application Device must be connected through an air tube with a sterile filter to a supply of pressurized gas (compressed air,
1
OMRIX biopharmaceuticals, Inc. Crosseal™Application Device Premarket Notification
nitrogen, CO2) via a pressure regulator, which is an accessory to the Application Device. For dripping, the Application Device can be used with or without pressurized gas. The device is ethylene oxide (EtO) sterilized. Intended Use:
The Crosseal" Application Device is intended for the simultaneous topical application of the two biological components of Crosseal Fibrin Sealant via dripping (no air pressure) or via spraying (utilizing the pressure regulator unit) onto the surface of the liver in patients undergoing liver surgery.
Similar Technical Characteristics between Crosseal Application Device and Duploject®
| Characteristic | Crosseal™ Application Device | Duploject® |
|---|---|---|
| Indications | Intended for use in the simultaneous | |
| delivery of the two solutions of | ||
| Crosseal™ Fibrin Sealant onto the | ||
| surface of the liver in patients | ||
| undergoing liver surgery. | Intended for use in the simultaneous | |
| delivery of two non-homogeneous | ||
| fluids or solutions onto a surgical site. | ||
| Syringe Volume | 1.0 mL, 2.0 mL, and 5.0 mL | 0.5/1.0 mL, 2.0 mL, and 5.0 mL |
| Delivery Accuracy | The slide bar on the syringe holder | |
| ensures delivery of equal amounts of | ||
| the contents of the syringes. | The slide bar on the syringe holder | |
| ensures delivery of equal amounts of | ||
| the contents of the syringes. | ||
| Syringe Assembly | Syringes preassembled into syringe | |
| holster. Syringe pistons yoke-coupled. | Syringes preassembled into syringe | |
| holster. Syringe pistons yoke-coupled | ||
| Method of drawing | ||
| solutions into syringes | Mixject Dispensing Pin with | |
| Detachable Vial Holder | Syringe needles | |
| Catheter Tip | Tri-lumen tip configuration, | |
| Malleable cannula | Bi-lumen tip configuration, | |
| malleable cannula | ||
| Use | Single-use, disposable for hospital use | Single-use, disposable for hospital use |
| Sterilization | EtO | EtO |
2
Similar Technical Characteristics between Crosseal™ Application Device and Tissomat® and Spray Set
| Characteristic | Crosseal™ Application Device | Tissomat® and Spray Set |
|---|---|---|
| Indications | Intended for use in the simultaneous | |
| application by dripping or spraying of | ||
| the two components of Crosseal™ | ||
| Fibrin Sealant onto wound surfaces. | Intended for use in the simultaneous | |
| application by spraying of the two | ||
| components of Tisseel Fibrin Sealant | ||
| onto wound surfaces. | ||
| Gas Supply | Compressed air, nitrogen, or CO2 | Compressed air, nitrogen, or CO2 |
| Spraying distance | 10 to 15 cm | Minimum of 10 cm |
| Recommended gas | ||
| pressure | 2 to 3 bars (30 to 40 psi) | Maximum of 2 bars (28.5 psi) |
Performance Information:
Use of the spray application technology is supported by performance testing studies that determined the optimal gas pressure range and the optimal distance that the spray catheter is required to be from the surgical tissue surface to obtain uniformity of mixing and consistency of spray spread. The optimal gas pressure (34psi) and optimal spray distance 10-15 cm was evaluated in two U.S. pivotal Phase III clinical trials. There were no adverse events associated with this system and the clinical studies demonstrated that this is an efficacious method of providing optimal coverage of fibrin sealant onto the surgical tissue surface.
Summary of Biocompatibility Tests:
- A Primary Skin Irritation Evaluation was conducted using a test extract of the . device. Under the conditions of the test, the test article extract was found to not produce skin irritation.
- A Guinea Pig Maximization was performed using a test extract of the device. . Under conditions of the test, the Test Article, extracted in normal saline, was found to not produce sensitization.
- A Cytotoxicity Test (MEM Elution Test) was performed using a test extract of . the device. Under conditions of the test, the Test Article was found to be noncytotoxic.
- An Acute Systemic Toxicity Test was conducted using a test extract of the ● device. Under conditions of the test, there was no reaction of the mice to the Test article when observed at intervals of a period of 72 hours following treatment.
3
- A Pyrogenicity Test (Limulus Test)-Materials Mediated, was performed using . a test extract of the device. Under conditions of the test, the Test Article was found to be non-pyrogenic.
- Two studies were conducted to determine hemocompatibility: an in vitro . hemolysis study (modified ASTM - Direct Contact Method) and a determination of clotting time using the Lee-White Method. The studies revealed that the test article was non-hemolytic, and did not biologically effect the clotting time.
Conclusions:
The intended use, design, materials of fabrication and performance of the Crosseal" Application Device are substantially equivalent to both the Duploject and the Tissomat and Spray Set. Differences in spray parameters (spray distance, pressure) have been justified through both laboratory performance testing and human clinical trials. It is concluded that the Crosseal" Application Device is substantially equivalent to these legally marketed devices.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines above them that resemble a bird in flight.
Public Health Service
MAR 2 1 2003
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
OMRIX Biopharmaceuticals, Incorporated Ms. Sue Bhadare Consultant CRO Fessionals, LLC 6599 Commerce Court, Suite 200 Warrenton, Virginia 20187
Re: K030032
Trade/Device Name: Crosseal Application Device Regulation Number: 880.5860 Regulation Name: Piston Syringe Regulatory Class: II Product Code: FMI Dated: January 3, 2003 Received: January 3, 2003
Dear Ms. Bhadare:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting vour device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2 - Ms. Bhadare
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801): good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4618. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Susan Runner, DDS, MA
Interim Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
4.0 INDICATIONS FOR USE
510(k) Number:
Device Name: Crosseal™ Application Device
Classification: Class II
Product Code: 80FMF, Piston Syringe
Indications for Use:
The Crosseal™ Application Device is intended for the simultaneous topical application of the two biological components of Crosseal™ Fibrin Sealant via dripping (no air pressure) or via spraying (with air pressure utilizing the pressure regulator unit) onto the surface of the liver in patients undergoing liver surgery.
Concurrence of CDRH, Office of Device Evaluation (ODE)
Patricio Cucente
(Division Sign-Off) (Division Sign-Off)
Division of Anesthesiology, General Hospital, Division of Anesthesion Control, Dental Devices
510(k) Number: K030032
Prescription Use (Per 21 C.F.R. 801 109)
Or
Over-the-Counter Use _________________________________________________________________________________________________________________________________________________________
4-1